Arvinas (NASDAQ:ARVN) CEO Randy Teel Sells 2,209 Shares

Arvinas, Inc. (NASDAQ:ARVN) CEO Randy Teel sold 2,209 shares of the business’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $9.04, for a total transaction of $19,969.36. Following the transaction, the chief executive officer owned 285,009 shares of the company’s stock, valued at $2,576,481.36. This trade represents a 0.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Randy Teel also recently made the following trade(s):

• On Monday, May 11th, Randy Teel sold 9,657 shares of Arvinas stock. The shares were sold at an average price of $9.94, for a total transaction of $95,990.58.
• On Monday, February 23rd, Randy Teel sold 4,786 shares of Arvinas stock. The shares were sold at an average price of $12.16, for a total transaction of $58,197.76.

Arvinas Trading Down 0.1%

Shares of ARVN traded down $0.01 during mid-day trading on Friday, reaching $9.09. 778,275 shares of the stock traded hands, compared to its average volume of 864,744. The firm has a fifty day moving average price of $10.59 and a 200 day moving average price of $11.66. The company has a market cap of $586.49 million, a price-to-earnings ratio of -2.74 and a beta of 1.79. Arvinas, Inc. has a 1 year low of $6.05 and a 1 year high of $14.51.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.90) EPS for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.05. The firm had revenue of $15.60 million during the quarter, compared to analyst estimates of $16.61 million. Arvinas had a negative net margin of 247.54% and a negative return on equity of 44.38%. The business’s revenue for the quarter was down 91.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.14 EPS. On average, sell-side analysts anticipate that Arvinas, Inc. will post -2.85 EPS for the current year.

Institutional Trading of Arvinas

Hedge funds and other institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC grew its position in Arvinas by 491.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock valued at $43,000 after acquiring an additional 4,835 shares during the last quarter. Canada Pension Plan Investment Board lifted its holdings in shares of Arvinas by 109.4% in the 2nd quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock worth $49,000 after acquiring an additional 3,500 shares during the last quarter. State of Wyoming purchased a new stake in shares of Arvinas in the 3rd quarter valued at $68,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Arvinas in the 3rd quarter valued at $92,000. Finally, Jain Global LLC purchased a new stake in shares of Arvinas in the 3rd quarter valued at $95,000. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. BTIG Research boosted their price target on shares of Arvinas from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, May 13th. Truist Financial set a $10.00 price target on shares of Arvinas in a research report on Wednesday, March 18th. Zacks Research lowered shares of Arvinas from a “hold” rating to a “strong sell” rating in a research report on Monday, April 27th. Piper Sandler reiterated an “overweight” rating and issued a $20.00 target price (up from $16.00) on shares of Arvinas in a research report on Wednesday, February 25th. Finally, Wedbush upped their target price on shares of Arvinas from $9.00 to $11.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 24th. Eight investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, Arvinas presently has a consensus rating of “Hold” and a consensus target price of $14.69.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.